[go: up one dir, main page]

MX2011010324A - Tableta recubierta que se desintegra oralmente. - Google Patents

Tableta recubierta que se desintegra oralmente.

Info

Publication number
MX2011010324A
MX2011010324A MX2011010324A MX2011010324A MX2011010324A MX 2011010324 A MX2011010324 A MX 2011010324A MX 2011010324 A MX2011010324 A MX 2011010324A MX 2011010324 A MX2011010324 A MX 2011010324A MX 2011010324 A MX2011010324 A MX 2011010324A
Authority
MX
Mexico
Prior art keywords
orally disintegrating
coated tablet
coating layer
disintegrating coated
medicament
Prior art date
Application number
MX2011010324A
Other languages
English (en)
Inventor
Kotoe Ohta
Suguru Takaki
Yasuhide Horiuchi
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of MX2011010324A publication Critical patent/MX2011010324A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una tableta recubierta estable que se desintegra oralmente conteniendo un fármaco en donde la tableta se recubre con una capa de recubrimiento conteniendo una sustancia soluble en agua y una resina de poli (alcohol vinilico ) de no menos de 5% por peso con base en el peso de la capa de recubrimiento, la sustancia soluble en agua disolviéndose en una cantidad de 1g o mas en menos de 10 ml de agua a 20° C, teniendo grupos hidroxilo en su molécula, y teniendo un peso molecular de no más de 200 por unidad de grupo hidroxilo. Se proporciona una tableta recubierta estable que se desintegra oralmente que no ocasiona una fractura en la capa de recubrimiento aun cuando la tableta que se desintegra oralmente ha sido hinchada por absorción de humedad bajo alta humedad, mientras que asegura propiedades de rápida desintegración en una cavidad oral. En el caso de una tableta que se desintegra oralmente conteniendo un fármaco inestable a al a luz, degradación del fármaco puede suprimirse mediante mezclar físicamente un agente que obscurece la luz en la capa de recubrimiento. Superficie.
MX2011010324A 2009-03-30 2010-03-29 Tableta recubierta que se desintegra oralmente. MX2011010324A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009081916 2009-03-30
PCT/JP2010/055517 WO2010113841A1 (ja) 2009-03-30 2010-03-29 口腔内崩壊性被覆錠剤

Publications (1)

Publication Number Publication Date
MX2011010324A true MX2011010324A (es) 2011-12-16

Family

ID=42828131

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011010324A MX2011010324A (es) 2009-03-30 2010-03-29 Tableta recubierta que se desintegra oralmente.

Country Status (15)

Country Link
US (1) US8715730B2 (es)
EP (1) EP2415466B1 (es)
JP (2) JP5549586B2 (es)
KR (1) KR101682965B1 (es)
CN (1) CN102448445B (es)
AU (1) AU2010231701B2 (es)
BR (1) BRPI1014085B1 (es)
CA (1) CA2756877C (es)
ES (1) ES2572761T3 (es)
HU (1) HUE028195T2 (es)
MX (1) MX2011010324A (es)
PL (1) PL2415466T3 (es)
PT (1) PT2415466T (es)
TW (1) TWI455733B (es)
WO (1) WO2010113841A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110117133A (ko) * 2009-01-29 2011-10-26 다이닛본 스미토모 세이야꾸 가부시끼가이샤 내핵을 갖는 구강 내 붕괴 정
JP5782312B2 (ja) * 2011-07-01 2015-09-24 日新化成株式会社 コーティング用組成物
JP5916091B2 (ja) * 2012-01-31 2016-05-11 大原薬品工業株式会社 口腔内崩壊錠のｕｖレーザー印刷方法
US20150164831A1 (en) * 2012-03-30 2015-06-18 Takeda Pharmaceuticals U.S.A., Inc. Colchicine formulations; methods of making; and methods of use thereof
BR112014026439B1 (pt) * 2012-04-27 2022-05-31 Merck Patent Gmbh Formulação farmacêutica sob a forma de um comprimido revestido, e seu processo de preparação
EP2674149B1 (en) * 2012-06-15 2017-10-04 Shin-Etsu Chemical Co., Ltd. Method of preparing composite granule comprising low-substituted hydroxypropyl cellulose and rapid release preparation
JP6107226B2 (ja) * 2013-02-26 2017-04-05 ニプロ株式会社 医薬組成物
WO2014157264A1 (ja) * 2013-03-27 2014-10-02 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 口腔内崩壊性フィルムコーティング錠
JP6182744B2 (ja) * 2013-03-29 2017-08-23 三笠製薬株式会社 ナルフラフィン含有経皮吸収貼付剤
WO2015122477A1 (ja) * 2014-02-12 2015-08-20 沢井製薬株式会社 フィルムコーティングされた口腔内崩壊錠
TWI658842B (zh) 2014-03-31 2019-05-11 日商東麗股份有限公司 固體製劑用之被覆劑以及由其所形成之被膜及被覆固體製劑
CN104473882B (zh) * 2014-12-25 2018-10-02 北京华禧联合科技发展有限公司 一种甲钴胺颗粒
WO2016108250A1 (en) 2015-01-01 2016-07-07 Ideal Cures Pvt. Ltd. Novel film coating composition
JPWO2016163403A1 (ja) * 2015-04-07 2018-02-01 ニプロ株式会社 経口フィルム製剤
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
TW201707703A (zh) * 2015-06-04 2017-03-01 Tokai Capsule Co Ltd 軟膠囊劑
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN119157840A (zh) 2016-07-29 2024-12-20 东丽株式会社 光稳定性提高的固体制剂
CN107865827B (zh) * 2016-09-28 2022-04-05 四川海思科制药有限公司 一种聚普瑞锌口腔崩解片药物组合物及其制备方法
CN106562976A (zh) * 2016-10-17 2017-04-19 吉林省博大伟业制药有限公司 聚普瑞锌在制备治疗结肠癌药物中的应用
JP7153197B2 (ja) * 2017-03-31 2022-10-14 東レ株式会社 ナルフラフィンを含有する錠剤化された医薬組成物
WO2019075127A1 (en) 2017-10-10 2019-04-18 Vertice Pharma, Llc ORAL MICODRIN HYDROCHLORIDE SOLUTION AND USES THEREOF
AU2019229892B2 (en) 2018-03-08 2025-01-30 University Of Kansas Treatment of demyelinating diseases
KR102120720B1 (ko) 2018-07-16 2020-06-10 연성정밀화학(주) 날푸라핀 함유 구강붕해정
JP2021536467A (ja) 2018-09-06 2021-12-27 インノファーマスクリーン インコーポレイテッド 喘息またはパーキンソン病の処置のための方法および組成物
MX2018011699A (es) 2018-09-26 2019-07-24 Federico Amezcua Amezcua Composicion farmaceutica sinergica de un antagonista de los receptores de leucotrienos y un agonista inverso de la histamina h1.
JP7219979B2 (ja) * 2020-02-26 2023-02-09 日新製薬株式会社 被覆層を有する口腔内崩壊錠
JP2021175742A (ja) * 2020-04-24 2021-11-04 日本ジェネリック株式会社 温湿度安定性及び口腔内崩壊性に優れた口腔内崩壊性被覆錠剤
GB2636158A (en) 2023-12-01 2025-06-11 Novumgen Ltd An orally disintegrating tablet containing amlodipine or pharmaceutically acceptable salts thereof and the process of preparing the same

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5428812A (en) 1977-08-09 1979-03-03 Yoshitomi Pharmaceut Ind Ltd Preparation of coated tablet
AU680345B2 (en) * 1994-01-27 1997-07-24 Board Of Regents Of The University Of Oklahoma, The Rapidly dissolving oral dosage form
US6207199B1 (en) 1994-01-27 2001-03-27 The Board Of Regents Of The University Of Oklahoma Process for making a particulate support matrix for making a rapidly dissolving dosage form
JP3274573B2 (ja) * 1994-08-25 2002-04-15 興和株式会社 フィルムコーティング組成物およびそれを用いた固形製剤
DE69824277T2 (de) 1997-07-11 2004-09-23 Toray Industries, Inc. Stabile medizinische zusammenstellungen die 4,5-epoxymorphinanderivate enthalten
JP3460538B2 (ja) 1997-10-08 2003-10-27 救急薬品工業株式会社 速溶性フィルム製剤
JP4465728B2 (ja) 1998-12-10 2010-05-19 大正製薬株式会社 糖衣錠
US6448323B1 (en) * 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
US6801919B2 (en) 2001-07-27 2004-10-05 Hewlett-Packard Development Company, L.P. Object oriented database interface encapsulation that allows for chronologically overlapping transactions in a multi-threaded environment
CA2474190A1 (en) * 2002-02-07 2003-08-14 Pharmacia Corporation Pharmaceutical dosage form for mucosal delivery
GB0204772D0 (en) 2002-02-28 2002-04-17 Phoqus Ltd Pharmaceutical dosage forms
GB0211620D0 (en) 2002-05-21 2002-07-03 Bioprogress Technology Ltd Powder compaction and enrobing
JP2006076971A (ja) * 2004-09-13 2006-03-23 Basf Ag 口腔内崩壊錠
EP1923074A4 (en) * 2005-08-10 2011-09-14 Shionogi & Co TABLET WHICH CAN BE ORALLY DISINTEGRATED
JP4879542B2 (ja) 2005-09-28 2012-02-22 京都薬品工業株式会社 フィルムコーティング錠剤
US20080085310A1 (en) * 2006-10-06 2008-04-10 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
JP2008261849A (ja) 2007-03-20 2008-10-30 Nippon Shinyaku Co Ltd 鎮痒物質のスクリーニング方法及び評価方法
PL2151241T3 (pl) 2007-04-26 2012-08-31 Toray Industries Trwały stały preparat zawierający pochodną 4,5-epoksymorfinanową
CA2686964A1 (en) * 2007-06-06 2008-12-11 Basf Se Pharmaceutical formulation for the production of rapidly disintegrating tablets
JP5428812B2 (ja) 2009-12-04 2014-02-26 富士通株式会社 業務支援装置および業務支援プログラム

Also Published As

Publication number Publication date
CN102448445A (zh) 2012-05-09
PL2415466T3 (pl) 2016-10-31
KR101682965B1 (ko) 2016-12-06
KR20110135870A (ko) 2011-12-19
PT2415466T (pt) 2016-07-14
WO2010113841A1 (ja) 2010-10-07
JP5696742B2 (ja) 2015-04-08
JP2013177438A (ja) 2013-09-09
AU2010231701B2 (en) 2015-04-09
CA2756877C (en) 2016-08-16
CA2756877A1 (en) 2010-10-07
TWI455733B (zh) 2014-10-11
EP2415466A4 (en) 2012-08-29
JPWO2010113841A1 (ja) 2012-10-11
US8715730B2 (en) 2014-05-06
EP2415466B1 (en) 2016-05-11
BRPI1014085B1 (pt) 2020-03-10
TW201038298A (en) 2010-11-01
ES2572761T3 (es) 2016-06-02
AU2010231701A1 (en) 2011-11-17
JP5549586B2 (ja) 2014-07-16
EP2415466A1 (en) 2012-02-08
BRPI1014085A2 (pt) 2016-04-19
HUE028195T2 (en) 2016-12-28
US20120058186A1 (en) 2012-03-08
CN102448445B (zh) 2014-03-05

Similar Documents

Publication Publication Date Title
MX2011010324A (es) Tableta recubierta que se desintegra oralmente.
DE602007010254D1 (de) Feste dosierungsform mit einem wirkstoff mit unterdrücktem geschmack
CY1125382T1 (el) Συνθεση για εισπνοη που περιεχει ακλιδινιο για τη θεραπευτικη αντιμετωπιση του ασθματος
MX2012003082A (es) Composiciones farmaceuticas para reducir la absorcion rapida de la dosis inducida por el alcohol.
WO2007095600A3 (en) Disintegrable oral films
WO2011084593A3 (en) Abuse-resistant formulations
EP3895698A3 (en) Pharmaceutical compositions comprising iron oxy-hydroxide
EP2210591A3 (en) Wet granulation tableting method using aqueous dispersion of low-substituted hydroxypropyl cellulose
WO2012079092A3 (en) Testosterone undecanoate compositions
EA201400972A1 (ru) Лекарственные формы немедленного высвобождения с защитой от несанкционированного применения
NZ597354A (en) Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
NZ595467A (en) Sublingual pharmaceutical composition comprising a neutral oil
MX2013007237A (es) Peliculas y composiciones que comprenden las mismas.
SI1933809T1 (sl) Sestavki za mazalno dajanje
PE20091574A1 (es) Sistema de administracion de drogas con efecto estabilizante
MX2012013021A (es) Formulaciones resistentes a alcohol.
TNSN07337A1 (en) Pharmaceutical composition comprising an indolylmaleimide derivative
MX2012004316A (es) Agente de recubrimiento de pelicula para la preparacion de solidos y preparacion de solidos utilizando el mismo.
HK1214519A1 (zh) 雙用途硫酸鹽口服藥物組合物片劑及其使用方法
TW200735863A (en) Dietary compositions for enhancing metabolism and reducing reactive oxygen species
CY1120050T1 (el) Φαρμακοτεχνικες μορφες για την αποδεσμευση δραστικων ενωσεων
CN107649096A (zh) 一种生物防霉剂
PL2252263T3 (pl) Postać galenowa do podawania tryptanów poprzez błonę śluzową policzka
UA36877U (ru) Противомикробная стоматологическая пленка для лечения заболеваний полости рта
WO2010095158A8 (en) Pharmaceutical composition containing microcolloidal silver and carboxymethyl beta glucan for disinfection of the nasal mucosae, and process for preparation thereof